Retropharyngeal Abscess Market Research Report- Forecast till 2027

Retropharyngeal abscess market research report: information by diagnosis (X-rays and computed tomography, blood tests, physical exam, others), by treatment (antibiotics, pain killers, surgical drainage, others), and by end-user-forecast till 2027

ID: MRFR/Pharma/3491-HCR | February 2021 | Region: Global | 110 pages

Retropharyngeal abscess Market Scenario 


A retropharyngeal abscess is a serious infection, usually starts in the lymph nodes, characterised by collection of pus at the back of the throat. Retropharyngeal abscess typically occurs in children under the age of eight, sometimes it can also affect adults. The symptoms of retropharyngeal abscess include difficulty or noisy breathing, difficulty and pain while swallowing, drooling, severe cough, severe throat pain, neck stiffness or swelling, muscle spasms in the neck among others. Retropharyngeal abscess is generally preceded by upper respiratory infections mostly a middle ear or sinus infection.


The causes of retropharyngeal abscess are trauma or injury, medical procedure, dental procedures, alcohol intake, diabetes, cancer, AIDS, weakened immune system or a chronic diseases such as tuberculosis and others. Other complications indicated are pneumonia, blood clots in the jugular vein, mediastinitis, osteomyelitis and others. If left untreated, retropharyngeal abscess infection can spread to other parts of the body resulting in septic shock and organ failure. In severe instances, a retropharyngeal abscess can lead to death. The most common bacteria involved are Streptococcus, Staphylococcus, and others. Other infections, such as HIV and tuberculosis can also cause the retropharyngeal abscess. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications. Retropharyngeal abscess also slightly more common in males than females.


The market drivers for global retropharyngeal abscess market, are rise in demand due to the growing younger and susceptible population, increasing screening, urgency of the retropharyngeal abscess treatment, and rise in risk factors. The rise in cases of retropharyngeal abscess due to increase in Methicillin-resistant Staphylococcus aureus (MRSA) infections also stimulates the market. The market restraints are complications such as risk of bleeding, infections, pain, especially during surgery, high cost of retropharyngeal abscess treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.


The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.


Figure 1          Global Retropharyngeal abscess Market by Treatment, 2016 (%) Global Retropharyngeal abscess Market


Segments 


The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.


Based on the diagnosis, the retropharyngeal abscess market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.


Based on the treatment, the retropharyngeal abscess market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.


Based on the end user, the retropharyngeal abscess market has been segmented as hospitals and clinics, research and academics and others.


Regional Analysis 


A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.


Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.


Asia Pacific retropharyngeal abscess market is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.


Key Players in the Global Retropharyngeal abscess Market 


Some of the key players profiled in the report are Merck KGaA, Johnson & Johnson, AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc., and others.


Intended Audience



  • Global Retropharyngeal abscess manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Research Methodology 


Retropharyngeal Abscess Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2017-2023: 5.9 billion
  CAGR   2017-2023: 4.5%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, treatment, and end user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Merck KGaA, Johnson & Johnson, AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc., and others
  Key Market Opportunities   Development of broad spectrum antibiotics
  Key Market Drivers

  • Rise in demand due to the growing younger and susceptible population
  • increasing screening, urgency of the retropharyngeal abscess treatment


  • Frequently Asked Questions (FAQ) :


    Retropharyngeal Abscess Market valuation would be USD 5.9 billion.

    Retropharyngeal Abscess Market CAGR would be 4.5% during the forecast period.

    End users mentioned in the Retropharyngeal Abscess Market report are hospitals & clinics, & academics, and others

    Germany would lead the Retropharyngeal Abscess Market.

    The Retropharyngeal Abscess Market players are Johnson & Johnson, Merck KGaA, Sanofi S.A., Pfizer, AstraZeneca plc, Novartis AG, Mylan N.V, GlaxoSmithKline plc., Teva pharmaceutical company, and others.

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Retropharyngeal Abscess Market, by Diagnosis

    6.2 X-rays and Computed Tomography

    6.2.1 Market Estimates & Forecast, 2020-2027

    6.3 Blood Tests

    6.3.1 Market Estimates & Forecast, 2020-2027

    6.4 Physical Exam

    6.4.1 Market Estimates & Forecast, 2020-2027

    6.5 Others

    6.5.1 Market Estimates & Forecast, 2020-2027

    7. Global Retropharyngeal Abscess Market, by Treatment

    7.1 Introduction

    7.2 Antibiotics

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.3 Pain Killers

    7.3.1 Market Estimates & Forecast, 2020-2027

    7.4 Surgical Drainage

    7.4.1 Market Estimates & Forecast, 2020-2027

    7.5 Others

    7.5.1 Market Estimates & Forecast, 2020-2027

    8. Global Retropharyngeal Abscess Market, by End User

    8.1 Introduction

    8.2 Hospitals and Clinics

    8.2.1 Market Estimates & Forecast, 2081-2027

    8.3 Research and Academics

    8.3.1 Market Estimates & Forecast, 2081-2027

    8.4 Others

    8.4.1 Market Estimates & Forecast, 2081-2027

    9. Global Retropharyngeal Abscess Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 U.S.

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 U.K

    9.3.1.4 Italy

    9.3.1.5 Spain

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    11. Company Profiles

    11.1 Merck KGaA

    11.1.1 Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 Key

    11.2 Johnson & Johnson

    11.2.1 Overview

    11.2.2 Product Overview

    11.2.3 Financials

    11.2.4 Key Developments

    11.3 AstraZeneca plc

    11.3.1 Overview

    11.3.2 Product Overview

    11.3.3 Financials

    11.3.4 Key Development

    11.4 Sanofi S.A.

    11.4.1 Overview

    11.4.2 Product Overview

    11.4.3 Financials

    11.4.4 Key Development

    11.5 Mylan N.V

    11.5.1 Overview

    11.5.2 Product Overview

    11.5.3 Financials

    11.5.4 Key Development

    11.6 Teva pharmaceutical industries

    11.6.1 Overview

    11.6.2 Product Overview

    11.6.3 Financials

    11.6.4 Key Development

    11.7 Novartis AG

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financials

    11.7.4 Key Development

    11.8 Pfizer

    11.8.1 Overview

    11.8.2 Product Overview

    11.8.3 Financials

    11.8.4 Key Development

    11.9 GlaxoSmithKline plc

    11.9.1 Overview

    11.9.2 Product Overview

    11.9.3 Financials

    11.9.4 Key Development

    12. MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Retropharyngeal Abscess Treatment Industry

    13. Appendix


    List of Tables

    TABLE 1 GLOBAL RETROPHARYNGEAL ABSCESS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 2 X-RAYS AND COMPUTED TOMOGRAPHY FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 3 BLOOD TESTS FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 4 PHYSICAL EXAM FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 5 OTHERS FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL RETROPHARYNGEAL ABSCESS MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 7 ANTIBIOTICS FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 8 PAIN KILLERS FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 9 SURGICAL DRAINAGE FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 10 OTHERS FOR RETROPHARYNGEAL ABSCESS MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 11 GLOBAL RETROPHARYNGEAL ABSCESS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 12 NORTH AMERICA RETROPHARYNGEAL ABSCESS MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 13 NORTH AMERICA RETROPHARYNGEAL ABSCESS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 14 NORTH AMERICA RETROPHARYNGEAL ABSCESS MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 15 NORTH AMERICA RETROPHARYNGEAL ABSCESS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 16 NORTH AMERICA RETROPHARYNGEAL ABSCESS MARKET BY REGION 2020-2027 (USD MILLION

    TABLE 17 EUROPE RETROPHARYNGEAL ABSCESS MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 18 EUROPE RETROPHARYNGEAL ABSCESS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 19 EUROPE RETROPHARYNGEAL ABSCESS MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 20 EUROPE RETROPHARYNGEAL ABSCESS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 21 ASIA PACIFIC RETROPHARYNGEAL ABSCESS MARKET BY REGION 2020-2027 (USD MILLION)

    TABLE 22 ASIA PACIFIC RETROPHARYNGEAL ABSCESS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 23 ASIA PACIFIC RETROPHARYNGEAL ABSCESS MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 24 ASIA PACIFIC RETROPHARYNGEAL ABSCESS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 25 ASIA PACIFIC RETROPHARYNGEAL ABSCESS MARKET BY REGION 2020-2027 (USD MILLION)

    TABLE 26 MIDDLE EAST & AFRICA RETROPHARYNGEAL ABSCESS MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 27 MIDDLE EAST & AFRICA RETROPHARYNGEAL ABSCESS MARKET, BY DIAGNOSIS 2020-2027 (USD MILLION)

    TABLE 28 MIDDLE EAST & AFRICA RETROPHARYNGEAL ABSCESS MARKET, BY TREATMENT 2020-2027 (USD MILLION)

    TABLE 29 MIDDLE EAST & AFRICA RETROPHARYNGEAL ABSCESS MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 30 MIDDLE EAST & AFRICA RETROPHARYNGEAL ABSCESS MARKET BY REGION 2020-2027 (USD MILLION

    List of Figures

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET DYNAMICS FOR GLOBAL RETROPHARYNGEAL ABSCESS MARKET

    FIGURE 3 GLOBAL RETROPHARYNGEAL ABSCESS MAKRET, BY SEGMENT, 2020

    FIGURE 4 GLOBAL RETROPHARYNGEAL ABSCESS SUCCESS MARKET, BY REGION

    FIGURE 5 GLOBAL RETROPHARYNGEAL ABSCESS MARKET SHARE, BY DIAGNOSIS 2020

    FIGURE 6 GLOBAL RETROPHARYNGEAL ABSCESS MARKET SHARE, BY TREATMENT 2020

    FIGURE 7 GLOBAL RETROPHARYNGEAL ABSCESS MARKET SHARE, BY END USER, 2020

    FIGURE 8 GLOBAL RETROPHARYNGEAL ABSCESS MARKET SHARE, 2020

    FIGURE 9 GLOBAL RETROPHARYNGEAL ABSCESS MARKET SHARE, BY REGION, 2020

    FIGURE 10 NORTH AMERICA RETROPHARYNGEAL ABSCESS MARKET SHARE, BY COUNTRY, 2020

    FIGURE 11 EUROPE RETROPHARYNGEAL ABSCESS MARKET SHARE, BY COUNTRY, 2020

    FIGURE 12 ASIA PACIFIC RETROPHARYNGEAL ABSCESS MARKET SHARE, BY COUNTRY, 2020

    FIGURE 13 MIDDLE EAST & AFRICA RETROPHARYNGEAL ABSCESS MARKET, BY REGION, 2020

    FIGURE 14 GLOBAL RETROPHARYNGEAL ABSCESS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 15 TEVA PHARMACEUTICAL COMPANY: KEY FINANCIALS

    FIGURE 16 TEVA PHARMACEUTICAL COMPANY: SEGMENTAL REVENUE

    FIGURE 17 TEVA PHARMACEUTICAL COMPANY: GEOGRAPHICAL REVENUE

    FIGURE 18 RELIANT PHARMACEUTICALS: KEY FINANCIALS

    FIGURE 19 RELIANT PHARMACEUTICALS: SEGMENTAL REVENUE

    FIGURE 20 RELIANT PHARMACEUTICALS: GEOGRAPHICAL REVENUE

    FIGURE 21 GLAXOSMITHKLINE PLC: KEY FINANCIALS

    FIGURE 22 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

    FIGURE 23 GLAXOSMITHKLINE PLC: GEOGRAPHICAL REVENUE

    FIGURE 24 SANOFI S.A: KEY FINANCIALS

    FIGURE 25 SANOFI S.A: SEGMENTAL REVENUE

    FIGURE 26 SANOFI S.A: GEOGRAPHICAL REVENUE

    FIGURE 27 NOVARTIS AG: FINANCIAL REVENUE

    FIGURE 28 NOVARTIS AG: SEGMENTAL REVENUE

    FIGURE 29 NOVARTIS AG: GEOGRPAHICAL REVENUE